Tumor models have demonstrated that CD4+ tumor-reactive T cells have been shown to eradicate an MHC class I positive but class II negative tumor in the absence of CD8+ T cells for brain neoplasms, possibly showing the importance of interactions between CD4+ T cells and MHC class II expressing tumor-associated cells (83). This evidence concerns the gene HLA-C and neoplasm.